Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Although macroautophagy/autophagy is involved in hepatocellular carcinoma (HCC) initiation and development and has been identified as a mechanism of HCC therapy resistance, the role of ULK1 (unc-51 like autophagy activating kinase 1) in HCC remains unclear. Here, we report that both knockdown and knockout of inhibited human HCC cell proliferation and invasion, and deletion abrogated tumor growth in a xenograft mouse model. Furthermore, ablation in combination with sorafenib significantly inhibited HCC progression compared with sorafenib treatment alone or vehicle control. To identify candidate ULK1 inhibitors, we used a structure-based virtual docking approach to screen 3428 compounds. Among these compounds, XST-14 showed the highest affinity for the ULK1 protein and specifically blocked ULK1 kinase activity. Moreover, the Lys46, Tyr94 and Asp165 amino acid residues of ULK1 were required for its binding to XST-14 according to molecular docking and mutagenesis experiments. Functional assays revealed that XST-14 blocked autophagy and subsequently induced apoptosis and inhibited growth in HCC cells. More importantly, XST-14 acted synergistically with sorafenib to attenuate HCC progression by inhibiting sorafenib-induced autophagy activation both and . In addition, XST-14 was well tolerated and exhibited favorable drug metabolism and pharmacokinetic properties and low toxicity in mice. In summary, our study determined that ULK1 may represent a new therapeutic target for HCC and that targeting ULK1 in combination with sorafenib treatment may serve as a promising interventional strategy for treating HCC. 3MA: 3-methyladenine; ADV: AutoDock Vina; ATP: adenosine triphosphate; EdU: 5-ethynyl-2'-deoxyuridine; ESI: electrospray ionization; HCC: hepatocellular carcinoma; IC: half maximal inhibitory concentration; KD: kinase domain; q.o.d., every other day; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; SPR, surface plasmon resonance.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8386607PMC
http://dx.doi.org/10.1080/15548627.2019.1709762DOI Listing

Publication Analysis

Top Keywords

hepatocellular carcinoma
12
hcc
10
ulk1
8
combination sorafenib
8
hcc progression
8
sorafenib treatment
8
xst-14
5
role key
4
autophagy
4
key autophagy
4

Similar Publications

Purpose: Targeted therapy with lenvatinib is a preferred option for advanced hepatocellular carcinoma, however, predicting its efficacy remains challenging. This study aimed to build a nomogram integrating clinicoradiological indicators and radiomics features to predict the response to lenvatinib in patients with hepatocellular carcinoma.

Methods: This study included 211 patients with hepatocellular carcinoma from two centers, who were allocated into the training (107 patients), internal test (46 patients) and external test set(58 patients).

View Article and Find Full Text PDF

Agranulocytosis is an extremely rare but potentially fatal immune-related adverse event (irAE) induced by immune checkpoint inhibitors (ICIs). Its management, particularly following combination therapies such as durvalumab/tremelimumab (Dur/Tre) for hepatocellular carcinoma (HCC), is challenging owing to limited data. We herein report a 79-year-old man with HCC who developed severe Dur/Tre-induced agranulocytosis that was refractory to granulocyte colony-stimulating factor, high-dose corticosteroids, and intravenous immunoglobulin.

View Article and Find Full Text PDF

Introduction: Combined vascular endothelial growth factor/programmed death-ligand 1 blockade through atezolizumab/bevacizumab (A/B) is the current standard of care in advanced hepatocellular carcinoma (HCC). A/B substantially improved objective response rates compared with tyrosine kinase inhibitor sorafenib; however, a majority of patients will still not respond to A/B. Strong scientific rationale and emerging clinical data suggest that faecal microbiota transfer (FMT) may improve antitumour immune response on PD-(L)1 blockade.

View Article and Find Full Text PDF